Didrovaltrate is a synthetic opioid analgesic that is structurally related to methadone. It was first synthesized in the 1960s and has been studied for its potential therapeutic effects in pain management. Didrovaltrate is a mixed agonist-antagonist opioid, meaning that it can activate some opioid receptors while blocking others. This unique pharmacological profile has led to interest in didrovaltrate for the treatment of chronic pain, as well as for its potential to reduce opioid dependence. Didrovaltrate is not currently approved for medical use in the United States, but it is available in other countries. Research on didrovaltrate has focused on its efficacy and safety in managing pain, as well as its potential for reducing opioid abuse and dependence. However, more research is needed to fully understand the clinical utility of this drug. '
```
didrovaltrate: RN given refers to (1S-(1alpha,4aalpha,6alpha,7beta,7aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65689 |
| CHEMBL ID | 550227 |
| CHEBI ID | 4517 |
| SCHEMBL ID | 424675 |
| MeSH ID | M0083282 |
| Synonym |
|---|
| isovaltrate,5-dihydro- |
| butanoic acid, 6-(acetyloxy)-4a,5,6,7a-tetrahydro-4-[(3-methyl-1-oxobutoxy)methyl]spiro[cyclopenta[c]pyran-7(1h),2'-oxiran]-1-yl ester, [1s-(1.alpha.,4a.alpha.,6.alpha.,7.beta.,7a.alpha.)]- |
| nsc335756 |
| isovaleric acid,4-diester with 3a,4,5,6-tetrahydro-6-(hydroxymethyl)spiro[benzofuran-2(3h),2'-oxirane-3,4-diol, 6-acetate |
| dihydroisovaltrate |
| 1,5,7a-tetrahydro-1,6-dihydroxyspiro[cyclopenta[c]pyran-7(6h),2'-oxirane]-4-methanol 6-acetate 1,4-diisovalerate |
| isovalepotriate, dihydro- |
| isovaltrate, dihydro- |
| nsc-335756 |
| didrovaltrate [inn] |
| isovaleric acid, 3,4-diester with 3a,4,5,6-tetrahydro-6-(hydroxymethyl)spiro(benzofuran-2(3h),2'-oxirane)-3,4-diol, 6-acetate |
| dihydroisovaltratum |
| didrovaltrato [inn-spanish] |
| nsc 335756 |
| isovaltrate, 4a,5-dihydro- |
| dihydroisovalepotriate |
| didrovaltrat [german] |
| einecs 242-175-8 |
| 1,4a,5,7a-tetrahydro-1,6-dihydroxyspiro(cyclopenta(c)pyran-7(6h),2'-oxirane)-4-methanol 6-acetate 1,4-diisovalerate |
| (7s)-6alpha-acetoxy-1-alpha-isovaleryloxy-4-isovaleryloxymethyl-1,4aalpha,5,6,7,7aalpha-hexahydrocyclopenta(c)pyran-7-spiro-2'-oxiran |
| ccris 2662 |
| butanoic acid, 3-methyl-, (1s,4as,6s,2'r,7as)-6-(acetyloxy)-4a,5,6,7a-tetrahydro-4-((3-methyl-1-oxobutoxy)methyl)spiro(cyclopenta(c)pyran-7(1h),2'-oxiran)-1-yl ester |
| brn 6010565 |
| didrovaltratum [inn-latin] |
| butanoic acid, 3-methyl-, 6-(acetyloxy)-4a,5,6,7a-tetrahydro-4-((3-methyl-1-oxobutoxy)methyl)spiro(cyclopenta(c)pyran-7(1h),2'-oxiran)-1-yl ester, (1s-(1-alpha,4a-alpha,6-alpha,7-beta,7a-alpha))- |
| 18296-45-2 |
| didrovaltrate |
| C09776 |
| LMPR0102070008 |
| [(1s,4as,6s,7r,7as)-6-acetyloxy-1-(3-methylbutanoyloxy)spiro[4a,5,6,7a-tetrahydro-1h-cyclopenta[c]pyran-7,2'-oxirane]-4-yl]methyl 3-methylbutanoate |
| CHEMBL550227 |
| chebi:4517 , |
| didrovaltrat |
| didrovaltrato |
| ken63d125f , |
| unii-ken63d125f |
| didrovaltrate [mart.] |
| butanoic acid, 3-methyl-, (1s,2'r,4as,6s,7as)-6-(acetyloxy)-4a,5,6,7a-tetrahydro-4-((3-methyl-1-oxobutoxy)methyl)spiro(cyclopenta(c)pyran-7(1h),2'-oxiran)-1-yl ester |
| SCHEMBL424675 |
| DTXSID80171363 , |
| HY-N3741 |
| CS-0024137 |
| ((1s,4as,6s,7r,7as)-6-acetoxy-1-((3-methylbutanoyl)oxy)-4a,5,6,7a-tetrahydro-1h-spiro[cyclopenta[c]pyran-7,2'-oxiran]-4-yl)methyl 3-methylbutanoate |
| Q27106405 |
| XD178328 |
| dtxcid9093854 |
| didrovaltrate (mart.) |
| AKOS040761620 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Compounds with free SH groups like cysteine, mercaptoethanol, dithioerythritol, and glutathione were able to suppress the cytotoxicity of the valepotriates in a dose-dependent way, whereas compounds with blocked SH groups did not antagonize these toxic effects." | ( Effects of thiol compounds versus the cytotoxicity of valepotriates on cultured hepatoma cells. Anton, R; Beck, JP; Haag-Berrurier, M; Keochanthala-Bounthanh, C, 1990) | 0.28 |
| Class | Description |
|---|---|
| iridoid monoterpenoid | One of a class of monoterpenoids biosynthesized from isoprene and often intermediates in the biosynthesis of alkaloids. Iridoids usually consist of a cyclopentane ring fused to a six-membered oxygen heterocycle; cleavage of a bond in the cyclopentane ring gives rise to the subclass known as secoiridoids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID423379 | Cytotoxicity against human A549 cells after 24 hrs by MTT assay | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Acylated iridoids with cytotoxicity from Valeriana jatamansi. |
| AID423380 | Cytotoxicity against human HCT8 cells after 24 hrs by MTT assay | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Acylated iridoids with cytotoxicity from Valeriana jatamansi. |
| AID423381 | Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Acylated iridoids with cytotoxicity from Valeriana jatamansi. |
| AID423382 | Cytotoxicity against human PC3M cells after 24 hrs by MTT assay | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Acylated iridoids with cytotoxicity from Valeriana jatamansi. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.79) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||